SLURP1: The Potential Drug Target and Biomarker for Anti-Neoplastic Urinary Protein

Target Name: SLURP1

NCBI ID: G57152

SLURP1

SLURP1: The Potential Drug Target and Biomarker for Anti-Neoplastic Urinary Protein

Anti-neoplastic urinary protein (ANP) is a protein that is expressed in the urine of individuals with urinary tract cancer (UTC), and it has been identified as a potential biomarker and drug target in this disease. The Slcup gene, which encodes the protein ANP, has been identified as a promising gene for cancer research due to its potential involvement in the development and progression of various types of cancer. One of the challenges in the study of ANP is its limited expression and the difficulty in identifying reliable biomarkers for its detection in urine samples from patients with cancer. This article will discuss the potential of SLURP1 as a drug target and biomarker for ANP in the context of UTC.

The Importance of ANP in UTC

ANP is a key protein that is expressed in the urine of individuals with UTC. It is a component of the urine matrix and has been shown to play a role in the development and progression of various types of cancer, including UTC. ANP has been shown to be overexpressed in the urine samples of individuals with UTC compared to the urine samples of individuals without cancer. This increase in ANP expression is thought to contribute to the development of cancer-related changes in the urine samples of individuals with UTC.

The Potential of SLURP1 as a Drug Target

SLURP1 is a gene that encodes a protein known as SLURP1 (slcup-1). SLURP1 has been shown to be involved in the development and progression of various types of cancer, including UTC. Several studies have shown that SLURP1 is involved in the regulation of various cellular processes that are important for cancer growth and progression, including cell adhesion, migration, and angiogenesis.

One of the potential strategies for targeting SLURP1 in the context of UTC is to use small molecules or antibodies that specifically interact with SLURP1 to inhibit its activity. This approach is thought to be effective because SLURP1 is a protein that is expressed in high levels in the urine samples of individuals with UTC, making it an attractive target for drug development.

The Potential of SLURP1 as a Biomarker

SLURP1 has also been shown to be a potential biomarker for UTC. The identification of biomarkers for cancer has the potential to improve diagnosis and treatment outcomes for cancer patients. SLURP1 has been shown to be expressed in the urine samples of individuals with UTC, and several studies have shown that it is associated with poor prognosis in individuals with UTC.

One of the potential benefits of using SLURP1 as a biomarker for UTC is its potential utility as a diagnostic marker. By measuring the levels of SLURP1 in urine samples from individuals with UTC, healthcare professionals may be able to determine the stage of the disease and guide treatment decisions. Additionally, SLURP1 has been shown to be associated with the expression of other proteins that are involved in the development and progression of UTC, making it a potential marker for disease progression.

Conclusion

SLURP1 is a gene that encodes a protein that has been shown to be involved in the development and progression of various types of cancer, including UTC. The potential of SLURP1 as a drug target and biomarker for UTC is being investigated further to determine its utility in the context of this disease. Further research is needed to fully understand the role of SLURP1 in the development and progression of UTC and to identify effective strategies for its targeting and use as a biomarker

Protein Name: Secreted LY6/PLAUR Domain Containing 1

Functions: Has an antitumor activity (PubMed:8742060). Was found to be a marker of late differentiation of the skin. Implicated in maintaining the physiological and structural integrity of the keratinocyte layers of the skin (PubMed:14721776, PubMed:17008884). In vitro down-regulates keratinocyte proliferation; the function may involve the proposed role as modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro inhibits alpha-7-dependent nAChR currents in an allosteric manner (PubMed:14506129, PubMed:26905431). In T cells may be involved in regulation of intracellular Ca(2+) signaling (PubMed:17286989). Seems to have an immunomodulatory function in the cornea (By similarity). The function may implicate a possible role as a scavenger receptor for PLAU thereby blocking PLAU-dependent functions of PLAUR such as in cell migration and proliferation (PubMed:25168896)

The "SLURP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLURP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets